@UniofOxford @AstraZeneca COVID vaccine (modified chimp adenovirus bearing spike protein) effective!

Dose regimen 1 (1/2 dose + full dose): 90%
Dose regimen 2 (full + full): 62%
Avg regimens: 70%

Interim analysis 11K, 131 events
Fridge temp storage https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html

Did investigators expect 1/2 + full to outperform full + full?

Is there a scientific rationale for that?

Also, for either regimen, best news:

“Among those who received the vaccine, there were no severe cases of Covid-19 in the trial and no participants were hospitalized.“

vaccine that much of developing world has bought

“Oxford accounts for more than 40% of supplies going to those countries...costs a fraction of price set by Pfizer and will be manufactured in multiple countries, from India to Brazil...easier to deploy”

https://www.bloomberg.com/amp/news/articles/2020-11-22/astra-oxford-shot-is-key-to-escaping-pandemic-for-many-nations?__twitter_impression=true

Global order tracking

, fascinating

Oxford did say vaccine may prevent asymptomatic infections...

Pfizer/Moderna couldn't assess this

h/t @sciencescanner https://twitter.com/simonbayly/status/1330822021903691776

reminds me that clinical trial efficacy top line number is often about ENDPOINTS chosen https://twitter.com/simonbayly/status/1330822021903691776

@simonbayly looking a further into this. am not sure about your claim.

here is @EricTopol summary of the *primary endpoints* of the 3 trials. Looks like @AstraZeneca primary endpoint included symptoms

cc: @sciencescanner https://twitter.com/EricTopol/status/1307408470245691392